There is no single evidence-based duration that applies to every adult using compounded sermorelin for wellness goals. A clinic’s three- or six-month purchase option is a billing period, not proof that everyone should remain on treatment for that long.
Stopping questions deserve the same care as starting questions. The response depends on why treatment was prescribed, what changed during treatment, adverse effects, and the specific preparation. Ask the prescriber for a plan instead of adopting an online cycle or taper.
Duration should follow clinical benefit and safety review. A subscription term should not decide how long a medicine is used.
What long-term safety evidence leaves unanswered
Research in growth hormone-related treatments differs in molecule, route, population, and follow-up. Short-term tolerance does not establish safety over many years, especially for uncommon outcomes. A small study cannot support a promise that indefinite wellness use is harmless.
Ask which evidence supports the proposed length of therapy and whether the original goal has improved meaningfully. The cancer-risk article discusses one area where blanket reassurance is inappropriate; other symptoms and laboratory findings also belong in the review.
Cycling is not a substitute for evidence
An online schedule of weeks on and weeks off may look precise without being validated for the product or patient. A claim that cycling prevents tolerance or guarantees safety needs evidence; repetition across forums is not that evidence.
Do not change frequency, pause, or restart to copy a bodybuilding protocol. The prescriber should explain the actual schedule and what to do if treatment is interrupted. The timing guide addresses practical schedule questions without creating a universal regimen.
What happens after discontinuation?
It is reasonable to ask whether a laboratory response or perceived benefit will persist, but permanent results should not be promised. The underlying condition and other treatments do not disappear when a prescription ends. A change after stopping can also reflect changes in sleep, exercise, nutrition, or expectations.
Ask the clinician what should be monitored after discontinuation and how to distinguish recurrence of the original concern from a new problem. Do not assume that everyone needs a taper, that nobody does, or that a different peptide should automatically replace sermorelin.
Separate the medical plan from cancellation
Stopping medication and cancelling an automatic refill are two different actions. A clinician may advise a treatment change while an account still has a scheduled charge. Conversely, cancelling a subscription does not provide clinical instructions for the remaining medicine.
Keep the prescriber’s plan and the company’s cancellation confirmation. Ask about refill cutoffs, unused medication, and future charges before a long prepaid commitment. Our subscriptions and refunds guide explains the financial details, and the worth-it article helps organize reassessment.
Sources behind this article
Provider pages describe their own services. They are not independent proof of health outcomes. Pricing and availability can change.
- Endotext: Growth Hormone and AgingExpert clinical evidence review · Separates hormone and body-composition findings from functional outcomes and long-term unknowns.
- Sigalos and Pastuszak: Safety and efficacy of growth hormone secretagoguesClinical or regulatory reference · Checked September 20, 2026. Findings apply to the specified molecule, route, and population.
- Mayo Clinic: Sermorelin injection informationClinical or regulatory reference · Checked September 20, 2026. Findings apply to the specified molecule, route, and population.
- Endocrine Society: Adult growth hormone deficiencyClinical practice guideline · Diagnosis and treatment of established deficiency; not an endorsement of anti-aging prescribing.
- FDA: Compounding questions and answersUS regulator · Compounded medicines differ from FDA-approved generic drugs.